tbuckley/cabot-search huggingface dataset:
Cancer and Venous Thromboembolism
Authors: A J Hilson
Journal: New England Journal of Medicine (1998)

Venous thromboembolism (VTE) is a collective term for pulmonary embolism and deep venous thrombosis.VTE is a common finding and a leading cause of death in cancer patients.This underlines the need for exploring risk factors for cancer-related VTE to enable prophylactic treatment in high-risk patients.It is also known that VTE may represent the first sign of an undetected cancer.The first aim of this thesis was to investigate whether leukocyteand platelet counts measured prior to cancer diagnosis were associated with risk of VTE in cancer patients and in subjects who remained cancer-free during follow-up.Secondly, we aimed to study the risk of cancer in patients with and without VTE and explore whether different VTE characteristics were associated with an increased risk of subsequent cancer.In paper I and II, our study population was recruited from the fourth survey of the Tromsø Study (Tromsø 4) conducted in 1994-1995, which included more than 27000 participants.Paper III and IV are based on the Scandinavian Thrombosis and Cancer (STAC) Cohort, which comprises individual data from the Tromsø 4 Study, the second Nord-Trøndelag Health Study (HUNT 2), and the Danish Diet, Cancer and Health Study and includes almost 145000 participants.Validated VTE events and cancer diagnoses in all papers have been registered from inclusion (1993-1997) to the end of follow-up (2007-2012).The incidence rates of VTE in the Tromsø 4 Study (1994-2009) was 13.5 per 1000 person-years in cancer patients and 1.2 per 1000 person-years in cancer-free patients.In cancer patients, both pre-cancer leukocyte-and platelet counts above the 80 th percentile were associated with a two-fold increased risk of VTE compared to the 40 th percentile, and high levels of both parameters had a synergistic effect on risk of VTE.Conversely, no associations between these parameters and VTE were found in cancer-free subjects.Our findings suggest that leukocyte-and platelet counts may play a role in the pathogenesis of cancer-related VTE.In the STAC Cohort, we assessed the risk of cancer after VTE.The incidence rates of cancer were 60.6 per 1000 person-years the first year after VTE and 9.5 per 1000 personyears in VTE-free subjects.Subjects with VTE had a 4-fold higher multivariable-adjusted cancer risk than subjects without VTE the first year after VTE and a 1.3-fold higher risk during subsequent years.The anatomical location of VTE was not predictive of cancer risk, and only minor differences in cancer risk were found in subjects with unprovoked and provoked VTE.These results suggest that future studies investigating the benefits of examination for an undetected cancer after VTE should not be restricted by these factors.
The contribution of the European high containment laboratories during the 2014–2015 Ebola Virus Disease emergency
Authors: C. Nisii, D. Vincenti, F.M. Fusco, J. Schmidt-Chanasit, C. Carbonnelle, H. Raoul, M. Eickmann, R. Hewson, A. Brave, S. Nuncio, M.P. Sanchez-Seco, B. Palyi, Z. Kis, S. Zange, A. Nitsche, A. Kurth, M. Strasser, M.R. Capobianchi, A. Ozin, P. Guglielmetti, C. Menel-Lemos, D. Jacob, R. Grunow, G. Ippolito, A. Di Caro
Journal: Clinical Microbiology and Infection (2016)
Effect of race on the safety and efficacy outcomes of gemcitabine plus paclitaxel treated patients with metastatic breast cancer (MBC): Analyses from a phase III trial
Authors: Y. Wang, D. Tai, L. Zhao, J. Gill, C. K. Obasaju
Journal: Journal of Clinical Oncology (2009)

1070 Background: Population-based studies often attribute racial disparities in breast cancer outcomes to differences in access to treatment, quality of care, or other socioeconomic factors. In a controlled clinical trial setting, these systemic differences between races should be minimal. To evaluate the potential impact of race on outcomes in a controlled clinical setting, we retrospectively analyzed data from a phase III trial (B9E-MC-JHQG; NCT00006459 ) of patients (pts) with MBC. Methods: Analyses were performed on the JHQG trial database after 440 total pt deaths for both study arms. Demographics, safety, and efficacy were analyzed using safety population data from 3 racial groups: Caucasian (CA), Asian (AS), and Hispanic (HP). CA was the reference for all pair-wise comparisons. The logistic model was used to calculate odds ratios for tumor response and the Cox model was used to calculate hazard ratios for time-to-event parameters, adjusting for significant prognostic factors. Results: We report analyses of the gemcitabine (G) + paclitaxel (T) treatment arm. Demographics were balanced across the 3 groups with the exception that ER+/PR+ status was lower for AS compared to CA and HP; unknown ER/PR status was higher for AS. AS had significantly less neutropenia, fatigue, and nausea, but more anemia compared to CA and HP. Median number of treatment cycles completed was lower, but mean dose intensities for G and T were slightly higher, for AS. Response rate and progression-free survival were similar in the 3 groups. Overall survival (OS) and post-study chemotherapy (PSC) were significantly reduced for AS. Conclusions: Our analysis suggests that AS pts were better able to tolerate GT therapy compared to CA and HP pts. However, AS pts had the poorest OS outcome of the 3 racial groups, potentially due to reduced participation in PSC. [Table: see text] [Table: see text]
A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function.
Authors: M. W. Saif, M. Lichinitser, M. S. Gordon, B. R. Tan, M. E. Scheulen, N. B. Pandya, J. Sarantopoulos, J. J. Rinehart, C. F. Verschraegen, H. Lenz, C. Zergebel, K. Saito
Journal: Journal of Clinical Oncology (2011)

e13089 Background: S‐1 is an oral fluoropyrimidine that combines tegafur with two modulators, gimeracil and oteracil potassium. This study was designed to evaluate the PK of S-1 components (FT, CDHP, and Oxo) and the metabolites (5-FU, FBAL, CA) after single and multiple doses of S-1 administered to pts with renal impairment. Methods: This phase I study was conducted in 2 parts (PK Phase and Extension Phase). During the PK Phase, pts were stratified into 4 cohorts: Normal (CrCL >80 mL/min); Mild (CrCL of 51 to 80 mL/min); Moderate (CrCL of 30 to 50 mL/min); Severe (CrCL <30 mL/min). S-1 dosing was determined by degree of renal impairment: 20 mg/m2 QD (severe); 20 mg/m2 BID (moderate); 30 mg/m2 BID (mild), and 30 mg/m2 BID (normal) for 14 days followed by a 1‐week off period. 6 pts were enrolled into each cohort. Plasma and urine were collected to measure the concentrations of S-1 components and its metabolites on day -2 through 48 hrs after the first administration of a single dose of S-1, day 7 and 14. Results: There was no DLTs in the normal (n=7) or moderate(n=6) cohorts. One of 6 pts in the mild cohort experienced 4 DLTs: Gr 3 diarrhea, Gr 3 mucosal inflammation, Gr 3 dehydration, and Gr 3 blood creatinine increased. For the single dose 5-FU and CDHP data, there was statistically significant increase in AUC0-inf value for the mild cohort relative to the normal cohort. For the multiple dose 5-FU, CDHP, Oxo, FBAL, CA, and uracil data, there were no statistically significant differences in Cmax or AUC 0-12 values for the mild or moderate cohort relative to the normal cohort. As compared to normal cohort, there was no evidence of increased accumulation of S-1 components or metabolites following multiple-dose administration in mild or moderate cohort. Conclusions: Based on the results from the single dose PK, a dose reduction from 30 mg/m2 BID to 25 mg/m2 BID for pts with mild renal impairment, 20 mg/m2 BID for pts with moderate renal impairment should be considered for S-1 monotherapy. Data on the severe cohort will be presented at the meeting. S-1 was generally well tolerated in this population with normal renal function, and mild or moderate renal impairment.
G-CSF-Primed Bone Marrow As a Source of Hematopoietic Stem Cells for Allogeneic Transplantation in Malignant and Non-Malignant Hematological Disorders
Authors: Eucario León-Rodríguez, Patricia Guzmán-Uribe, Marcela Deffis Court, Sandra Ileana Perez-Alvarez, Monica M Rivera Franco
Journal: Blood (2014)
A memorable patient: Ben
Authors: John S N Anderson
Journal: BMJ (2006)

Ben was one of those delightful patients who put up with much but never complained. He had his first heart attack in 1975, but his real claim to fame was in 1985 when he appeared in a cardiology textbook. Seated at a Guy's Hospital lipid clinic, aged 63, he faced the camera to show his xanthelasma and his blood pressure being measured, while continuing to smoke his cigarette.
Case 18-1971
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, George A. Jacoby, John B. Blennerhassett, Edward P. Richardson
Journal: New England Journal of Medicine (1971)

Presentation of CaseA 58-year-old man was brought to the hospital by police after having collapsed.He was known to be a chronic alcoholic, with one episode of delirium tremens in the past. Emphysema had been present for four or five years. He was separated from his wife and lived alone, consuming unknown quantities of alcohol. On the day before admission he spoke by telephone to his daughter, who believed that he sounded about as usual. No further information could be obtained.Physical examination revealed an acutely ill, disheveled man who mumbled a few incomprehensible words and stared vacantly at . . .
Black Lives
Authors: Jeremy O’Connor
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts From the Emerging Science Series, June 27, 2011
Journal: Circulation (2011)

Introduction: End Stage Renal Disease (ESRD) is one of the most costly chronic diseases in the industrialized world.In the U.S., more than $27 billion is expended annually for the care of 400,000 dialysis patients.Creation and maintenance of access shunts is one of the principal challenges associated with dialysis, and accounts for 15% of all ESRD-related expenses.A more effective solution to hemodialysis access remains one of the key objectives in vascular surgery today.Previously we reported promising results with the first human patients to receive a completely autologous tissue engineered vascular graft (TEVG) for hemodialysis access.With time points out to 3 years, we observed a 2.4-fold reduction in events relative to the pre-enrollment rates with the standard of care.The complexities of the autologous model, however, make it difficult to translate to widespread clinical use.We hypothesized that an allogeneic TEVG, available 'off-the-shelf,' would have similar benefits and may demonstrate improved efficacy and cost-effectiveness relative to synthetic grafts.Here we report the first human use of an allogeneic TEVG.Methods: TEVGs were built from allogeneic fibroblasts using a process termed Sheet-based Tissue Engineering.30 cm long grafts with a diameter of 4.8 mm were built from cellular sheets without the inclusion of exogenous biomaterials.The lab-grown grafts were implanted as a shunt between the brachial artery and the axillary vein in three patients with ESRD.No HLA matching was performed.Results: With time points ranging from 1-7 months, all grafts are patent, with flow rates in excess of 600 ml/min.Doppler ultrasound exams show a normal pulse wave, and no changes in diameter or wall structure.Blood laboratory results are all within expected ranges, and lymphocytotoxic cross reactivity tests were uniformly negative.Conclusion: The allogeneic TEVGs do not initiate short-term immune reactions, and appear to tolerate both the hemodynamic loads and the needle punctures associated with hemodialysis access.This short-term result, coupled with the dramatic reduction in event rate for the autologous studies, suggests that an off-the-shelf TEVG with improved efficacy relative to the standard of care may finally be within reach.
Genome-wide association scans identify novel loci that influence lipid levels and risk of coronary artery disease
Authors: S S Najjar, C J Willer, S Sanna, A U Jackson, A Scuteri, R Clarke, P Galan, P Meneton, D Zelenika, J Sundvall, R M Watanabe, A R Shuldiner, R Collins, R N Bergman, M Uda, J Tuomilehto, F S Collins, G M Lathrop, M Boehnke, D Schlessinger, G R Abecasis, A Cao, K L Mohlke, E G Lakatta
Journal: Circulation Research (2007)
Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas
Authors: Ulas Solmaz, Emre Mat, Atalay Ekin, Cenk Gezer, Alper Biler, Nuri Peker, Duygu Ayaz, Muzaffer Sanci
Journal: International Journal of Surgery (2016)
A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (FP).
Authors: Hansjochen Wilke, David Cunningham, Atsushi Ohtsu, Ulrike Nuber, Rolf Bruns, Beate Schmitt-Bormann
Journal: Journal of Clinical Oncology (2012)

TPS4139 Background: Vascular endothelial growth factor (VEGF) expression in gastric cancer (GC) is associated with more aggressive clinical disease. VEGF expression in resected GC is associated with tumor recurrence and shorter survival. Data from Phase 2 and 3 studies suggest that agents targeting the VEGF pathway improve the efficacy of some chemotherapy regimens in 1st- and 2nd-line treatment of patients with gastric or gastroesophageal carcinomas. RAM, a fully human monoclonal antibody, binds to the VEGF receptor-2 (VEGFR-2), potently blocks the binding of VEGF to VEGFR-2, inhibits VEGF-stimulated activation of VEGFR-2, and neutralizes VEGF-induced mitogenesis of human endothelial cells. Methods: Pts are randomized 1:1 to receive PTX + RAM or PTX + PBO until disease progression or intolerable toxicity (28-day cycle; RAM/PBO 8 mg/kg Days 1, 15; PTX 80 mg/m 2 Days 1, 8, 15). Eligibility includes metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma; prior first-line therapy with any PLT/FP doublet with or without anthracycline; progressive disease during or following first-line therapy; ECOG PS 0-1; bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 3 × ULN for ALAT/ASAT if no liver metastases, &lt; 5 × ULN if liver metastases; creatinine ≤ 1.5 × ULN; absolute neutrophil count ≥ 1.5 × 10 9 /L, hemoglobin ≥ 9 g/dL; platelets ≥ 100 × 10 9 /L. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival, time to progression, best overall response, objective response rate, safety, patient-reported outcome measures, pharmacodynamics, immunogenicity, and pharmacokinetics. This study, powered at 90% to show an increase in OS (mdn: 7 m PTX + PBO, 9.33 m PTX + RAM) at a 1-sided 2.5% significance level, will randomize 663 pts. As of 18 January 2012, approximately 58% of planned pts were randomized. The IDMC reviewed this study 23 June and 01 December 2011 and recommended the study continue unmodified.
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
Authors: K. Suzuki, T. Yamanaka, H. Hashimoto, Y. Shimada, K. Arata, R. Matsui, K. Goto, T. Takiguchi, F. Ohyanagi, Y. Kogure, N. Nogami, M. Nakao, K. Takeda, K. Azuma, S. Nagase, T. Hayashi, K. Fujiwara, T. Shimada, N. Seki, N. Yamamoto
Journal: Annals of Oncology (2016)
Endoscopic treatment of a duodenal invagination
Authors: Pablo Miranda-Garcia, Juan Ignacio Tellechea, Jean Michel Gonzales, Adrian Culetto, Marc Barthet
Journal: Endoscopy (2015)

A 47-year-old man was referred to North Hospital with a 2-month history of recurrent occlusive syndrome. Findings on computed tomography scan ([Fig. 1]) and endoscopy led to a diagnosis of duodenal invagination and partial duodenal atresia. Endoscopic therapy was performed ([Video 1]).
Mutations in linker for activation of T cells (LAT) lead to a novel form of severe combined immunodeficiency
Authors: Chiara Bacchelli, Federico A. Moretti, Marlene Carmo, Stuart Adams, Horia C. Stanescu, Kerra Pearce, Manisha Madkaikar, Kimberly C. Gilmour, Adeline K. Nicholas, C. Geoffrey Woods, Robert Kleta, Phil L. Beales, Waseem Qasim, H. Bobby Gaspar
Journal: Journal of Allergy and Clinical Immunology (2016)
CATARACTS AND ALOPECIA UNIVERSALIS
Authors: J F DINGMAN, N Y LIM
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis
Authors: Josiah D Rich, Curt G Beckwith, Alexandria Macmadu, Brandon D L Marshall, Lauren Brinkley-Rubinstein, Joseph J Amon, M-J Milloy, Maximilian R F King, Jorge Sanchez, Lukoye Atwoli, Frederick L Altice
Journal: The Lancet (2016)
Flower Power—The Versatility of Bloodroot
Authors: Eric L. Maranda, Mindy X. Wang, Jacqueline Cortizo, Samantha Hsieh, Dagmara Danek, Joaquin J. Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma
Authors: Andreas Rosenwald, German Ott, Karen Pulford, Tiemo Katzenberger, Joachim Kühl, Jörg Kalla, M. Michaela Ott, David Y. Mason, Hans Konrad Müller-Hermelink
Journal: Blood (1999)
NF2 Activates Hippo Signaling and Promotes Ischemia/Reperfusion Injury in the Heart
Authors: Takahisa Matsuda, Peiyong Zhai, Sebastiano Sciarretta, Yu Zhang, Jae Im Jeong, Shohei Ikeda, Jiyeon Park, Chiao-Po Hsu, Bin Tian, Duojia Pan, Junichi Sadoshima, Dominic P. Del Re
Journal: Circulation Research (2016)

Rationale: NF2 (neurofibromin 2) is an established tumor suppressor that promotes apoptosis and inhibits growth in a variety of cell types, yet its function in cardiomyocytes remains largely unknown. Objective: We sought to determine the role of NF2 in cardiomyocyte apoptosis and ischemia/reperfusion (I/R) injury in the heart. Methods and Results: We investigated the function of NF2 in isolated cardiomyocytes and mouse myocardium at baseline and in response to oxidative stress. NF2 was activated in cardiomyocytes subjected to H 2 O 2 and in murine hearts subjected to I/R. Increased NF2 expression promoted the activation of Mst1 (mammalian sterile 20–like kinase 1) and the inhibition of Yap (Yes-associated protein), whereas knockdown of NF2 attenuated these responses after oxidative stress. NF2 increased the apoptosis of cardiomyocytes that appeared dependent on Mst1 activity. Mice deficient for NF2 in cardiomyocytes, NF2 cardiomyocyte-specific knockout (CKO), were protected against global I/R ex vivo and showed improved cardiac functional recovery. Moreover, NF2 cardiomyocyte-specific knockout mice were protected against I/R injury in vivo and showed the upregulation of Yap target gene expression. Mechanistically, we observed nuclear association between NF2 and its activator MYPT-1 (myosin phosphatase target subunit 1) in cardiomyocytes, and a subpopulation of stress-induced nuclear Mst1 was diminished in NF2 CKO hearts. Finally, mice deficient for both NF2 and Yap failed to show protection against I/R indicating that Yap is an important target of NF2 in the adult heart. Conclusions: NF2 is activated by oxidative stress in cardiomyocytes and mouse myocardium and facilitates apoptosis. NF2 promotes I/R injury through the activation of Mst1 and inhibition of Yap, thereby regulating Hippo signaling in the adult heart.